Core Viewpoint - Profusa, Inc. is launching its Healthcare Research version of the Lumee tissue oxygen monitoring system, which has led to a significant stock rally and increased trading volume [1]. Company Developments - The Lumee tissue oxygen products are now commercially available for contract research organizations (CROs), targeting a market projected to grow from approximately $47.9 billion in 2025 to over $91.2 billion by 2034 at a CAGR of more than 7% [2]. - The company has appointed Sean Givens to lead commercialization efforts, highlighting strong industry interest in their validated sensors [4]. Product Features - The Lumee tissue oxygen system will be offered as research-use-only kits, allowing CRO partners to integrate the technology into existing study designs with minimal implementation risk [3]. - This system provides continuous, real-time measurement of tissue oxygenation, offering critical insights for various applications, including advanced in vitro models and preclinical studies [3]. Market Performance - Profusa's stock is currently trading 21.2% above its 20-day simple moving average (SMA) but is 51.3% below its 100-day SMA, indicating a short-term bullish trend while facing longer-term challenges [5]. - The stock has decreased 94.35% over the past 12 months and is closer to its 52-week lows than highs [5]. Technical Analysis - The RSI is at 44.33, indicating a neutral territory with no immediate overbought or oversold conditions, while the MACD is above its signal line, suggesting bullish momentum [6]. - The combination of neutral RSI and bullish MACD indicates mixed momentum, leading to cautious optimism among traders [6]. Stock Price Action - Profusa stock is up 20.30% at $0.12 at the time of publication, with key resistance at $0.14 and key support at $0.09 [7].